Arrowstreet Capital’s Bright Minds Biosciences DRUG Stock Holding History

Arrowstreet Capital’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$505K	Buy	+7,199	New	+$565K	﹤0.01%	1754

Other funds holding DRUG

Jupiter Topco New York $245B AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Arrowstreet Capital's DRUG Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 7,199 shares worth $505K. The stake represents ﹤0.01% of the portfolio and ranks #1754 among its holdings.

100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

Arrowstreet Capital held 7,199 shares of Bright Minds Biosciences worth $505K as of Q2 2026.
Bright Minds Biosciences was a new Arrowstreet Capital position in Q2 2026.
Bright Minds Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1754 holding.
100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.